Licensing strategy for new qPCR assay to determine in-vitro cell contamination & cell-type verification

Challenge

A leading UK University was developing a ‘3-in-1’ PCR-based assay for rapid cell line verification and purity testing. The technology comprised a PCR-based assay containing novel markers for rapid, cost-effective human cell identification and validation, including STR genotyping and rodent/mycoplasma contamination testing.  The University was keen to progress with commercial engagement with a view to concluding a licensing agreement and required evidence-based guidance on the strategy and the next steps to achieving these goals, specifically including the following:

• Develop the value proposition for the technology and turn it into a pitch document to be used with prospective licensees/collaborators
• Develop a licensing strategy/plan including a plan for commercial engagement
• Provide support to licensing negotiations.  

Solution

Alacrita's consultants met with the Principal Investigator and proceeded to develop a licensing strategy & plan, including:

• Establishing the development status of the technology and reviewing commercialization efforts to date
• Confirming technology value proposition in key market applications and commercial exploitation model
• Developing non-confidential and confidential pitch documents
• Compiling a database of prospective licensees
• Developing a licensing strategy & plan

The pitch documents were successfully used to engage potential collaborators and interest was generated for partnership.